Trials / Completed
CompletedNCT03990090
A Study of TG103 in Chinese Healthy Adult Subjects
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase Ia Study in Chinese Healthy Adult Subjects to Investigate the Safety, Tolerability and Pharmacokinetic of TG103
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purposes of this study are to determine: 1. To assess the safety and tolerability of a single subcutaneous injection of different doses of TG103 in healthy Chinese adult subjects. 2. The pharmacokinetic and pharmacodynamic characteristics of a single subcutaneous injection of different doses of TG103 in healthy Chinese adult subjects were assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG103 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2019-07-29
- Primary completion
- 2020-11-11
- Completion
- 2020-11-11
- First posted
- 2019-06-18
- Last updated
- 2020-11-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03990090. Inclusion in this directory is not an endorsement.